Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

NCT04251182 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: 15mg T3D-959
DRUG: 30 mg T3D-959
DRUG: 45 mg T3D-959
DRUG: Placebos

Sponsor

T3D Therapeutics, Inc.

Collaborators

[object Object]
[object Object]
[object Object]